Abstract A cohort of nine patients, mostly young adults, presented with a new sign/symptom of pheochromocytoma/paraganglioma: exercise-induced nausea and vomiting. The aims of this article are to introduce this sign/ symptom and offer a possible hypothesis for the observation. Following a 2000 report from a paraganglioma patient experiencing exercise-induced nausea and vomiting, we began asking patients about instances of nausea and vomiting with exercise. A total of nine patients, 4.4% of our pheochromocytoma/paraganglioma population, presented with reports of exercise-induced nausea and vomiting, initially with moderate-to-intense levels of exercise, at the first presentation of their disease. All of these patients reported a cessation of exercise-induced nausea and vomiting following the removal of their primary tumor. Two patients with metastatic disease to the lungs reported a recurrence of exercise-induced nausea and vomiting. The majority of patients studied were young adults with mean onset age of 19.4 years (range of 9-51 years) and the mean age of diagnosis being 24.1 years (range of 11-53 years). Exercise-induced nausea and vomiting should be considered a sign/symptom of pheochromocytoma/paraganglioma and should be addressed in the clinical evaluation of these patients, especially in young adults. Whether exerciseinduced elevated catecholamine levels could account for the induced nausea and vomiting via activation of adrenergic receptors in the area postrema remains to be established.
Introduction
Pheochromocytomas and paragangliomas (chromaffin cell tumors of the sympathetic or parasympathetic ganglia) are diagnosed either biochemically based on the measurements of catecholamines and their metabolites in the blood and/or urine, or by specific imaging modalities [1] [2] [3] . The clinical manifestation of pheochromocytomas/paragangliomas secreting excess catecholamines is typically characterized by symptoms of elevated blood pressure, heart palpitations, increased perspiration, and anxiety [4] [5] [6] . Less commonly, pheochromocytoma/paraganglioma patients can present with signs and symptoms such as pallor, headaches, flushing, nausea, and vomiting, which often occur during hypertensive spells [5] . These events usually subside following the decrease in their plasma catecholamine levels.
In 2000 a 23-year-old man presented to the National Institutes of Health (NIH) for suspected pheochromocytoma/paraganglioma. The patient's history showed that he began experiencing episodes of nausea during intense exercise at age 20 (exercise level determined based on guidelines by the CDC and ACSM) especially when jogging and lifting weights, which would cause him to discontinue exercise after which he would vomit. These events became worse over the years to the point where he would vomit every time he exercised (even when exercise was considered light, such as brisk walking). Following the removal of the patient's primary abdominal tumor, exercise-induced nausea and vomiting ceased, and the patient has been free of these signs/symptoms since.
Subsequent to this report, we began asking patients about experiences with nausea during exercise, and nausea and vomiting after exercise. Throughout the clinical interview, physicians especially focused on a number of important questions surrounding patient's experiences with exercise-induced nausea and vomiting. During this investigation, a total of 206 patients with pheochromocytoma/ paraganglioma were studied at the NIH, and we have identified a cohort of nine patients who initially presented with exercise-induced nausea and vomiting.
Subjects and methods
A total of 206 patients with diagnosed pheochromocytoma/ paraganglioma have been studied at the NIH and nine of them initially presented with exercise-induced nausea and vomiting in addition to the classical symptoms of pheochromocytoma/paraganglioma on the first presentation of their disease.
On initial clinical evaluation all pheochromocytoma/ paraganglioma, patients were asked about their signs and symptoms related to catecholamine excess including whether or not they experienced exercise-induced nausea and vomiting. If the patient had experienced exercise-induced nausea and vomiting, they were asked specific questions including: (a) whether nausea and vomiting was only present during exercise or when they were sedentary; (b) what intensity of exercise initially induced nausea and vomiting; (c) whether the intensity of exercise or duration of exercise affected the severity of nausea and vomiting; (d) how long after exercise initiation did nausea and vomiting occur; (e) whether other signs/symptoms of pheochromocytoma/paraganglioma were involved; (f) whether their experiences of nausea and vomiting changed over time (e.g., did the patient begin experiencing nausea and vomiting after less intense exercise); and (g) whether exerciseinduced nausea and vomiting subsided after removal of the primary tumor. Thus, from the cohort of 206 pheochromocytoma/paraganglioma patients, we identified nine individuals who complained of exercise-induced nausea and vomiting on the first presentation of their disease.
Characteristics of these patients, outlined in Table 1 , show the mean age of symptom onset as 19.4 years (range: 9-51 years) and the average age of diagnosis as 24.1 years (range: 11-53 years). Biochemical data at first presentation to the NIH, but not necessarily the first presentation of disease, (patients gave informed consent prior to any testing at the National Institutes of Health) for the nine patients showed noradrenergic phenotypes ( Table 2) .
Occurrence of exercise-induced nausea and vomiting at the initial presentation of disease appeared at varied exercise levels ranging from light to intense, as defined by the CDC and ACSM guidelines [7] : with one patient stating initial presentation of the sign/symptom with light exercise, three patients with moderate exercise, two patients with moderate-to-intense exercise, and three patients with intense exercise (Table 3) . During and following physical Age of symptom onset age of onset of initial exercise-induced nausea and vomiting associated with pheochromocytoma/paraganglioma, Age of diagnosis age of diagnosis of pheochromocytoma/paraganglioma, Age of metastasis age of diagnosis of metastatic pheochromocytoma/paraganglioma, EPI epinephrine, F female, M male, Meta metastatic, MN metanephrine, NE norepinephrine, NMN normetanephrine, Pt patient a Biochemistry tests in patient 9 prior to testing at the NIH demonstrated elevated norepinephrine levels activity, these patients experienced the classical pheochromocytoma/paraganglioma symptoms of elevated blood pressure, heart palpitations, profuse sweating, in some cases headaches, and all concomitantly experienced nausea during exercise followed by vomiting at the cessation of exercise. The patients studied were all adequately conditioned, with the adults reporting having been exercising regularly until the signs/symptoms started, and the parents of the children stating that their offspring had been very active prior to the reported signs/symptoms. The majority of patients stated that the sign/symptom of exerciseinduced nausea and vomiting grew worse with time and that the sign/symptom could eventually be elicited during instances of light exercise (such as carrying a suitcase or picking up a child). Some learned to control the symptoms by backing off the exercise when starting to become nauseous in an attempt to avoid vomiting. Patients reported that on removal of the primary tumor, exercise-induced nausea and vomiting ceased (Table 3) . For ethical reasons, patients were never subjected to exercise tests to try and mimic the symptoms, nor were they encouraged to continue exercising following reports of these symptoms until the offending pheochromocytoma/ paraganglioma could be removed.
Six of the nine patients presented to our institution with metastatic disease, and one patient (patient 6) presented with metastatic lesions in the bones as well as a primary abdominal tumor, and all described experiencing exerciseinduced nausea and vomiting on the first presentation of their disease (not necessarily at the presentation of metastatic disease). Patients with metastatic lesions in the organs such as the lungs (patients 1 and 7) reported a recurrence of exercise-induced nausea and vomiting following the development of metastatic tumors. Those patients with metastatic lesions solely in the bones, however, did not report a recurrence of exercise-induced nausea and vomiting.
Interestingly, seven of the nine patients had SDHB gene mutations. Whether exercise-induced nausea and vomiting is more common in patients with SDHB mutations over other genetic mutations remains to be established.
Discussion
The early age of onset, noradrenergic biochemical phenotype, genetic mutation, and extraadrenal location of the primary tumor among these patients suggest that exerciseinduced nausea and vomiting may be an important sign/ symptom in some pheochromocytoma/paraganglioma patients.
Published research in dogs indicate that activation of a 2 -and possibly a 1 -adrenergic receptors in the area postrema, a chemoreceptor trigger zone located on the floor of the fourth ventricle in the brain stem, by catecholamines such as norepinephrine could be responsible for the induced nausea and vomiting exhibited in these patients [8] . The area postrema is a circumventricular organ that lacks blood brain barrier and thus could be accessible to compounds circulating in the blood [9] , including catecholamines in pheochromocytoma/paraganglioma patients. Indeed, systemic or intramuscular administration of epinephrine or selective a 2 -or a 1 -adrenoceptor agonists induce vomiting in dogs in a dose-dependent manner which can be selectively blocked by their corresponding antagonists [8] . Moreover, direct injection of norepinephrine and epinephrine into the third or the lateral ventricle have been shown to induce emesis, probably through activation of a 1 -and a 2 -adrenergic receptors in the chemoreceptor zone of the fourth ventricle [10] . Our results indicate that exercise increases the amount of circulating catecholamines in pheochromocytoma/paraganglioma patients, this could potentially lead to activation of adrenergic a 1 -and a 2 -receptors in the area postrema and therefore, would induce nausea and vomiting.
In clinical practice, low doses of clonidine are commonly used as an a 2 -adrenergic receptor agonist to support the biochemical diagnosis of pheochromocytoma/paraganglioma, which, at least theoretically, should also induce nausea and vomiting via the central nervous system [11, 12] . However, in our experience with clonidine testing, we have never had a patient complain of nausea or vomiting during or following the test. Recent studies also seem to support clonidine as a nausea suppressor as opposed to a nausea inducer [13] [14] [15] . This is based on the hypothesis that clonidine acts as a sedative as well as suppressing noradrenergic activity via activation of presynaptic a 2 -receptors [15] . Thus, combination of these two effects is thought to lead to its antiemetic nature [15] . On the other hand, activation of postsynaptic a 2 -adrenoceptors by large doses of catecholamines present in pheochromocytoma/ paraganglioma patients could lead to emesis.
Exercise is known to produce a variety of gastrointestinal disturbances including nausea, diarrhea, and abdominal cramps [16] . During exercise, blood flow is mainly directed toward working muscles, skin (for thermoregulation), the heart, and the brain at the expense of lessdemanding organs such as the visceral organs. The gastrointestinal symptoms associated with exercise could be a consequence of vasoconstriction of splanchic and mesenteric vascular beds as a result of increased activation of a 1 -adrenergic receptors due to increased release of norepinephrine from sympathetic nerves. The decrease in blood flow in the visceral organs may reduce the ''wash effect'' of cardiovascular system and the released emetogens (norepinehrine, serotonin, prostaglandins, or leukotrienes) during exercise may accumulate in the gastrointestinal tract to significant levels [16, 17] which could initiate the vomiting reflex either via stimulation of vagal afferents or through systemic activation of area postrema [18, 19] .
An additional 23 patients from the pheochromocytoma/ paraganglioma protocol at the NIH were found to experience nausea and/or vomiting though not related to exercise. In these patients, nausea and/or vomiting was elicited during a ''spell'' or ''episode'' which could be associated with high blood pressure, heart palpitations, and/or diaphoresis. Importantly, these patients experienced nausea and/or vomiting in a random manner with the sign/symptom occurring during a ''spell.'' This is in contrast to patients with exercise-induced nausea and vomiting, who experienced both events on physical activity which became more frequent and could be elicited with light exercise. Some patients, who did not experience exercise-induced nausea and vomiting, did suffer from nausea and/or vomiting upon tumor palpation including abdominal massage or on micturition in cases of patients with urinary bladder tumors. If tumor palpation results in the release of catecholamines from the tumor and ''spells'' are associated with excess catecholamine release, then our hypothesis that nausea and vomiting are elicited from the stimulation of a 1 -and a 2 -adrenergic receptors may still apply. Questions remain as to why some patients experience nausea and vomiting on exercise while others do not, and why some patients experience nausea and/or vomiting when not exercising.
The 4.4% of all pheochromocytoma/paraganglioma patients experiencing exercise-induced nausea and vomiting at first presentation of pheochromocytoma/paraganglioma may be an underestimation given that all the patients evaluated were not asked to report their exercise level. Furthermore, it is not known how many patients did not exercise at all and thus would not have reported the sign/symptom. Therefore, it is important that clinicians begin asking pheochromocytoma/paraganglioma patients if they have ever had experiences with exercise-induced nausea and vomiting. Patients should also be made aware of the correlation between pheochromocytoma/paraganglioma and exercise-induced nausea and vomiting.
We conclude that exercise-induced nausea and vomiting could be considered a potential sign/symptom of pheochromocytoma/paraganglioma and should be taken into account during clinical evaluation.
